Secretrophin Growth Matrix
Also known as: Secretrophin, Secretropin, Secretropin (SRx), Secretrophin Growth Matrix
Overview
Secretrophin Growth Matrix is a synthetic, non-peptide amino acid-based compound formulated as a dietary supplement. It is designed to act as a growth hormone secretagogue (GHS), stimulating the body's natural production and release of endogenous growth hormone (GH) and related growth factors such as IGF-1 and IGFBP-3. Unlike naturally derived compounds, Secretrophin is synthetically produced and delivered via a nanoliposomal system to enhance absorption. Its primary applications include increasing GH and IGF-1 levels, potentially benefiting individuals with GH deficiency, age-related decline in GH, or those seeking anabolic or anti-aging effects. The compound is believed to modulate neurohormonal pathways by suppressing somatostatin, stimulating growth hormone releasing hormone (GHRH), and acting as an agonist at dopaminergic and ghrelin receptors. While clinical observations and mechanistic studies on GHSs in general support its theoretical basis, specific peer-reviewed clinical research on Secretrophin itself is limited, with most available data stemming from clinical usage reports rather than independent randomized controlled trials.
Benefits
Secretrophin is clinically reported to increase GH production and release, with claims of up to a 650% increase in GH and associated growth factors like IGF-1 and IGFBP-3, based on non-peer-reviewed patient data. However, these figures lack confirmation from published randomized controlled trials (RCTs). By elevating GH and IGF-1, potential secondary benefits, consistent with the known effects of GH secretagogues, may include improvements in lean body mass, bone density, and metabolic function. This supplement could be particularly beneficial for individuals with GH deficiency, such as children with short stature, adults with GH insufficiency, or aging populations experiencing a natural decline in GH levels. While quantitative effect sizes for Secretrophin are not available in peer-reviewed literature, related GH secretagogues have shown statistically significant increases in IGF-1 and growth velocity in children. Hormonal effects typically manifest within days to weeks, though long-term benefits like growth require months of consistent use.
How it works
Secretrophin functions as a growth hormone secretagogue (GHS) primarily by modulating the hypothalamic-pituitary axis to enhance endogenous GH secretion. Its mechanism involves multiple biological pathways: it suppresses somatostatin, a hormone that inhibits GH release, thereby removing a natural brake on GH production. Concurrently, it stimulates the release of Growth Hormone-Releasing Hormone (GHRH), which directly promotes GH secretion from the pituitary gland. Furthermore, Secretrophin acts as an agonist at both dopaminergic and ghrelin receptors. Ghrelin receptors (GHSR) are known to play a crucial role in regulating GH secretion and may also influence appetite and metabolism. The compound's interaction with these receptors and pathways collectively leads to increased pulsatile release of GH. It is delivered via a nanoliposomal sublingual spray, a formulation designed to enhance its absorption and bioavailability.
Side effects
Specific peer-reviewed safety data for Secretrophin are not available. While GH secretagogues as a class generally exhibit good safety profiles in short-term studies, the safety profile of Secretrophin itself remains largely unestablished. Common side effects for Secretrophin are unknown, but GH secretagogues in general may cause transient effects such as edema (swelling), joint pain, or increased appetite. Uncommon and rare side effects for Secretrophin have not been reported. Potential drug interactions are also unknown, but caution is advised when used concurrently with dopaminergic drugs or other hormone therapies due to its proposed mechanism of action. Contraindications for Secretrophin have not been formally established; however, due to the growth-promoting effects of GH, it is generally advised to use caution in patients with active cancer or other proliferative diseases. Data regarding its safety in special populations, including children, pregnant or lactating women, or individuals with chronic illnesses, are limited.
Dosage
The manufacturer suggests a starting dosage of two sprays sublingually once daily, typically at bedtime. This timing aligns with the body's natural peak of growth hormone secretion. However, optimal dosage ranges and maximum safe doses for Secretrophin have not been established through independent clinical trials. The product is specifically formulated as a sublingual spray utilizing a nanoliposomal delivery system, which is intended to enhance its absorption and bioavailability compared to traditional oral forms. There are no reported required cofactors for its efficacy. While hormonal effects may be observed relatively quickly, clinical benefits often require longer-term use. It is important to note that overstimulation of GH may lead to transient decreases in GH/IGF-1 levels, which are reportedly reversible with dose adjustment, though specific guidelines for such adjustments are not detailed in peer-reviewed literature.
FAQs
Is Secretrophin safe?
Independent safety data for Secretrophin are not available. While GH secretagogues generally have acceptable short-term safety, the long-term effects of Secretrophin are unknown and require further research.
How quickly does it work?
Hormonal changes, such as increased GH and IGF-1 levels, may begin within days of use. However, observable clinical benefits, like improvements in body composition or bone density, typically require longer periods of consistent use.
Is it a drug?
Secretrophin is classified and marketed as a dietary supplement, not a prescription drug. This classification means it is not subject to the same rigorous testing and approval processes as pharmaceutical medications.
Can it cause GH overstimulation?
The manufacturer suggests that overstimulation of GH may cause transient decreases in GH/IGF-1 levels. These effects are reportedly reversible by adjusting the dosage, though specific guidelines are not provided.
Research Sources
- https://pmc.ncbi.nlm.nih.gov/articles/PMC5632578/ – This randomized controlled trial investigated the efficacy of GH secretagogues (hexarelin, GHRP-2) in children with short stature. The study found significant increases in IGF-1 levels and growth velocity over 6-24 months, supporting the general concept that GH secretagogues can effectively increase GH and IGF-1. However, this study did not specifically evaluate Secretrophin.
- https://pubmed.ncbi.nlm.nih.gov/33460513/ – This review focused on the biology of GHSR (Growth Hormone Secretagogue Receptor), detailing the neuroendocrine pathways involved in GH secretion, including the roles of ghrelin and dopaminergic receptor agonism. It provides a mechanistic rationale for how compounds like Secretrophin might work by influencing these pathways, but it does not include clinical trial data specific to Secretrophin.
- https://www.a4m.com/assets/pdf/medical-news/medical-news-spring-2011.pdf – This source appears to be a medical news publication from A4M (American Academy of Anti-Aging Medicine). It likely contains information or reports related to Secretrophin, potentially including clinical observations or promotional material, but it is not a peer-reviewed research study.
- https://www.ucprx.com/product-page/secretropin – This URL links to a product page for Secretropin, likely from a compounding pharmacy or distributor. It provides information on the product's intended use, dosage, and potentially some clinical claims or testimonials, but it does not represent independent, peer-reviewed research.
- https://www.rothfeldapothecary.com/products/secretropin – This URL also links to a product page for Secretropin from a different apothecary. Similar to the previous product page, it offers commercial information about the supplement, including its purported benefits and usage instructions, but it is not a source of independent scientific research or clinical trials.